Pozen, Inc.
6330 Quadrangle Drive
Suite 240
Chapel Hill
North Carolina
27514
United States
Tel: 919-490-0012
243 articles about Pozen, Inc.
-
Pozen, Inc. Announces Results From a Burden of Cardiovascular Disease Study: a Managed Care Perspective
4/5/2013
-
Pozen, Inc. to Present at the 25th Annual ROTH Conference
3/7/2013
-
Pozen, Inc. Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results
2/27/2013
-
Pozen, Inc. Presents Positive Phase 3 Results
2/8/2013
-
Pozen, Inc. Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference
2/8/2013
-
Pozen, Inc. Announces Positive Results for the PA8140-102 Bioavailability Study
11/16/2012
-
Pozen, Inc. Reports Positive Test Results for Proposed Aspirin Therapy
11/7/2012
-
Pozen, Inc. Announces PA32540 Provides Superior Antiplatlet Effects Over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx")
8/29/2012
-
Pozen, Inc. Provides Update on Its PA Program and Results of Its Type A Meeting With the FDA
8/24/2012
-
Pozen, Inc. Reports PA32540 / PA8140 Updates and Second Quarter 2012 Financial Results
8/1/2012
-
Pozen, Inc. Receives Patent on PA Products for Treatment of Cardiovascular Disease and Osteoarthritis
6/26/2012
-
FDA Says Pozen, Inc. Ulcer Drug May Need More Data, Shares Plunge
6/21/2012
-
Pozen, Inc.'s PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)
5/21/2012
-
Pozen, Inc. Announces Licensing Deal with Desitin Pharmaceuticals GmbH for MT 400 Migraine Treatment in 29 European Countries
5/8/2012
-
Pozen, Inc. Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results
5/1/2012
-
Pozen, Inc.'s PA32540 Meets Goals in Pivotal Phase 3 Studies; Stock Rises +0.71(14.79%) @ 10:15AM EDT
3/23/2012
-
Pozen, Inc. to Present at the 24th Annual ROTH Conference
3/1/2012
-
Pozen, Inc. Reports Fourth Quarter & Year End 2011 Results
2/28/2012
-
Pozen, Inc. Announces February 28, 2012 Webcast of Fourth Quarter & Year End 2011 Results
2/14/2012
-
Pozen, Inc.’s Digital Advisory Board to Speak at Annual ePharma Summit
2/2/2012